コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nctive polymorphic ventricular tachycardia ('torsades de pointes').
2 ion of the QT interval and/or development of torsades de pointes).
3 lead to interventions to reduce the risk of torsades de pointes.
4 sociated with the rare adverse drug reaction torsades de pointes.
5 adverse events including QT prolongation and torsades de pointes.
6 to hyperfunction of L-type channels, such as Torsades de Pointes.
7 quired and drug-induced long QT syndrome and torsades de pointes.
8 enic afterdepolarizations thought to trigger torsades de pointes.
9 ation and is associated with case reports of torsades de pointes.
10 es, which are thought to trigger episodes of torsades de pointes.
11 f repolarization are not capable of inducing torsades de pointes.
12 ar tachycardia displaying characteristics of torsades de pointes.
13 ciated with the potentially fatal arrhythmia torsades de pointes.
14 ally the polymorphic ventricular tachycardia torsades de pointes.
15 duced long QT interval syndrome (diLQTS) and torsades de pointes.
17 ssociated with complex arrhythmias including torsades de pointes and 2 degrees atrioventricular block
23 ontractions and fibrillations reminiscent of Torsades des Pointes arrhythmias, and they exhibit sever
24 se in the intracellular calcium may underlie torsades de pointes associated with intravenous tacrolim
26 nd Europe with diLQTS, defined as documented torsades de pointes during treatment with a QT-prolongin
27 ated in causing QT interval prolongation and torsades de pointes, errors in the use of medications th
28 ars, and cases of prolonged QTc interval and torsades de pointes have been described in HIV-infected
29 eats after aftercontractions occurred before torsades de pointes in an in vivo dog model of drug-indu
30 s used to examine susceptibility to acquired torsades de pointes in chronic atrioventricular block an
31 voke the life-threatening cardiac arrhythmia torsades de pointes in some, but not all, individuals.
32 ing of noncardiac medications known to cause torsades de pointes, including fluoroquinolones and intr
33 ion of the QT interval and the occurrence of torsades de pointes is similar to more expensive alterna
34 /31; 61%) versus WT (8/26; 31%; P<0.05), and Torsades de Pointes occurred more frequently (73% Cav3.1
35 nic atrioventricular block animals exhibited torsades de pointes on dofetilide, the arrhythmia was in
36 g class IC drugs, patients with low risk for torsades de pointes receiving selected class III agents,
40 rhythmic agent with the propensity to induce torsades de pointes, substantially inhibits the current.
42 cteristic of long QT syndrome (LQTS) include torsades de pointes (TdP) and/or 2 degrees atrioventricu
43 healthy subjects and may be associated with torsades de pointes (TdP) arrhythmia, we tested the hypo
44 teria that are associated with initiation of torsades de pointes (TdP) in patients with acquired (a-)
45 oal of this study was to identify markers of torsades de pointes (TdP) in patients with drug-associat
46 e used for AF, excessive QT prolongation and torsades de pointes (TdP) often occur shortly after sinu
49 a higher risk of lethal arrhythmias, called Torsades de pointes (TdP), compared to the opposite sex.
51 safety, including the risk of drug-induced 'torsades de pointes' (TdP) arrhythmia, is a major concer
53 QT-prolonging medications can predispose to torsades de pointes, there is a relative paucity of info
54 een shown to correlate with a higher risk of torsades de pointes, there is no established threshold b
55 it is not known if the risk of drug-induced torsades de pointes varies during the menstrual cycle.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。